Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Product › Details

cabotegravir

	Next higher product group	virostatic agent
	Status	2015-11-03 development pc existent
	Organisation	GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
	Today	GSK plc (LSE: GSK, NYSE: GSK)
	Group	GSK (Group)

Record changed: 2023-07-10

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for virostatic agent

[1] Exscientia plc. (12/5/23). "Press Release: Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza". Oxford....
[2] Memo Therapeutics AG. (11/02/23). "Press Release: Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients". Schlieren....
[3] Atriva Therapeutics GmbH. (11/9/22). "Press Release: Atriva Therapeutics Appoints Christian Pangratz as Chief Executive Officer, Implementing Planned Management Change". Tübingen, Frankfurt a.M. & Martinsried....
[4] Synklino ApS. (6/8/22). "Press Release: Synklino Completes Series A Raise of EUR 29.8 Million to Advance Clinical Trials of Its Drug Candidate for the Treatment of Cytomegalovirus (CMV)". Copenhagen....
[5] ReViral Ltd.. (4/7/22). "Press Release: Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates". New York, NY, London & Research Triangle Park, NC....
[6] Pneumagen Ltd.. (1/19/22). "Press Release: Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)". St Andrew...
[7] BioNTech SE. (1/11/22). "Press Release: BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants". Mainz & London....
[8] Exscientia Ltd.. (9/8/21). "Press Release: Exscientia Enters $70M Collaboration to Develop Anti-viral Therapeutics against Coronavirus and other Viruses with Pandemic Potential"....
[9] Exscientia Ltd.. (7/8/21). "Press Release: Exscientia Accelerates COVID-19 Drug Discovery Using AI". Oxford....
[10] ReViral Ltd.. (3/2/21). "Press Release: ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China". London, et al.....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)